U.S. Real Estate ETF returned 3.55% this quarter amid Fed rate cuts and improved financing conditions. Click here to analyze ...

Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi ...

The NWRF announced that USA Waste & Recycling and All American Waste as the first services companies to donate to the ...

The latest update is out from Monte Rosa Therapeutics ( (GLUE) ).

While we wait patiently for this upside, CUBE is paying us a 5.7%-yielding dividend. Between the yield, low- to ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, ...

Investing.com -- Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 3.5% after the company announced positive interim data from its Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...

Pre-biopsy MRIs can help doctors diagnose and treat prostate cancer more accurately. Here’s when you should get one.

I recently sat down with Sarah Edwards, who has transitioned from Chief Product Officer to Chief Product Strategy Officer at Kantata. The difference, ...